Navigation Links
Ultrasound Transducer Disinfection in Many Cases Insufficient

HAMBURG, Germany, December 11 /PRNewswire/ --

- New 'Trophon EPR' Device Offers Unique Solution

Current methods of ultrasound transducer disinfection are in many cases not sufficient for clinical practice. This is the latest alarming result issued by the Center for Disease Control and Prevention (CDC), the leading US public health agency, in its recently published Guideline for Disinfection and Sterilization in Healthcare Facilities (1). The guideline is the CDC's response to the rapidly evolving epidemiology of hospital-acquired infections such as Clostridium Difficile (2) or MRSA (3).

In light of this global threat, and with regard to the millions of ultrasound examinations conducted each day, Nanosonics' newest product innovation represents a long-needed milestone in the development of medical devices: due to its unique technology, the Trophon EPR completely satisfies all requirements of the new CDC guideline.

Whereas current methods for high-level disinfection of contaminated transvaginal and transrectal transducers (e.g. aldehydes, alcohol or chlorine) show considerable drawbacks, the Trophon EPR has been custom designed to disinfect intracavity and surface ultrasound transducers, while combining speed, safety and convenience. It delivers high-level disinfection plus (HLD+), including sporicidal efficacy, in only six minutes operating time. The fully automated device can be used directly at the point of care, is easy to operate and is environmentally friendly, leaving water and oxygen as the only by-products.

"We recognised the danger presented by the inadequate disinfection of ultrasound transducers, and know that the Trophon EPR will be indispensable for the urgently needed hygiene necessary in the medical sector, to guarantee the safety of each and every patient", explained David Radford, Director and CEO of Nanosonics Limited, Australia, prior to the impending market launch.

The product technology has been validated by major OEM's (e.g. Philips Healthcare and Siemens Medical Solutions) and dealer commitments have already been approved in several European countries. The European launch of the Trophon EPR is scheduled to start in the first half of 2009. An application for FDA regulatory approval (510k) is on target for lodgement in December 2008, with anticipated approval later in 2009 allowing marketing within North America. For more information about Nanosonics, the Trophon EPR and its platform technology (NanoNebulant(TM)) please visit the Company's websites at and

About Nanosonics

The company is of Australian origin, located in Alexandria, Sydney, with European headquarters in Hamburg, Germany. Nanosonics has been listed on the Australian Securities Exchange (NAN) and Frankfurt Stock Exchange (OQM) since 2007.

The company owns intellectual property relating to unique disinfection and sterilisation technologies, which can be suited to a variety of markets including the healthcare industry, food processing, room and space decontamination, and manufacturing.

Nanosonics is currently focused on developing infection control solutions for the global healthcare market. Initial applications are designed for the reprocessing of reusable medical instruments. The Trophon EPR is specifically designed to disinfect intracavity and surface ultrasound probes. Based on the NanoNebulant(TM) technology it surpasses the limitations of current methods by killing the most resilient micro-organisms, in a fast, safe and convenient way.

(1) Rutala WA, Weber DJ, Healthcare Infection Control Practices Advisory Committee. Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008.

(2) Association for Professionals in Infection Control and Epidemiology (APIC). Press release, Orlando, 11 November 2008: Intestinal infection afflicts 13 of 1,000 hospital patients; infection rates 6.5-20 times greater than previous estimates, new study says.

(3) Orsi GB. MRSA: an old and new enemy. Healthcare Infection 2008; 13:73-75.

    World Headquarters
    Nanosonics Ltd.
    Unit 24, 566 Gardeners Road
    Alexandria NSW 2015

    European Headquarters
    Nanosonics Europe GmbH
    Falkenried 88, House E
    20251 Hamburg

    Media Contact Europe
    pluspool GmbH
    Nikola Heimann
    Ballindamm 26
    20095 Hamburg

SOURCE Nanosonics Europe GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
2. Arobella Medical CEO is Issued U.S. Patent for Ultrasound Wound Therapy Technology
3. MedPro Installs 1000th Ultrasound System Worldwide
4. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
5. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
6. Siemens Showcases New ACUSON S2000 Ultrasound System, as Well as Worlds First Pocket Ultrasound System
7. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
8. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
9. Siemens New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow
10. ALOKA to Introduce New ProSound Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida
11. Memorial Medical First in Stanislaus County to Provide Convertible Ultrasound From ZONARE
Post Your Comments:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):